Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

Autor: Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, Mark A Sydenham, Abdulla Alhasso, David J Bloomfield, Charlie Chan, Mark Churn, Susan Cleator, Charlotte E Coles, Andrew Goodman, Adrian Harnett, Penelope Hopwood, Anna M Kirby, Cliona C Kirwan, Carolyn Morris, Zohal Nabi, Elinor Sawyer, Navita Somaiah, Liba Stones, Isabel Syndikus, Judith M Bliss, John R Yarnold, Anne Armstrong, Judith Bliss, David Bloomfield, Jo Bowen, Murray Brunt, Hannah Chantler, Charlotte Coles, Ellen Donovan, Andy Goodman, Susan Griffin, Jo Haviland, Penny Hopwood, Anna Kirby, Julie Kirk, Cliona Kirwan, Marjory MacLennan, Mark Sculphur, Judith Sinclair, Mark Sydenham, Jean Tremlett, Karen Venables, Duncan Wheatley, John Yarnold

Publikováno v: Lancet (London, England)
FAST-Forward Trial Management Group 2020, ' Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward) : 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial ', Lancet (London, England), vol. 395, no. 10237, pp. 1613-1626 . https://doi.org/10.1016/S0140-6736(20)30932-6

BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after pri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e395035946033bfb3c8db03e2d044a